Voltar à classificação

Reckitt Benckiser Group plc (RBGPF)

NEUTRAL
Consumer DefensiveHousehold & Personal ProductsUnited Kingdom

Fundamental

52

Preço

$5150.00

Capitalização de Mercado

$32.48B

Parte 1 · Quanto vale a empresa

Visão Geral

Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.

Como gera receita

Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.

Vantagem competitiva

Marca · Estreita

Reckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.

O que impulsiona a procura

Defensivo

Most of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.

Os argumentos a favor

Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.

Os argumentos contra

Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.

Written by the editors, published on 18 de agosto de 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balanço & Liquidez

Receita

$13.35B

Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação

Resultado Líquido

$2.81B

Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação

Fluxo de Caixa Livre

$3.09B

Capital Próprio Total

$5.67B

Passivo Total

$10.25B

Rácio de Liquidez

0.59

Cobertura de Juros

-

Dívida/EBITDA

2.86

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

Sobrevalorizada

Valor Justo

$2156.36

Preço Atual

$5150.00

Margem de Segurança

-138.8%

Intervalo de Valor Justo

$1401.63 - $2911.08

Métodos de Estimativa

Analyst Target:$6223.26
DCF:$178.69
PE-based:$61.40
Graham Growth:$220.37
EPV:$42.58
Consenso dos Analistas:Compra Forte (22B / 7H / 0S)
Última Surpresa de Resultados:-1.27%

Métricas de Avaliação

Rácio P/E

1169.99

ROE

48.0%

Rácio P/B

580.17

P/FCF

1049.76

Margem Bruta

59.6%

ROIC

12.3%

Radar de Rentabilidade

Value Creation (Economic Moat)

ROIC

12.3%

WACC

8.5%

ROIC − WACC

+3.8 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Critérios de Análise Fundamental

Aprovado (10)

  • ROIC 12.3%
  • Gross Margin 59.6%
  • Debt/Equity ratio
  • Operating Margin 28.5%
  • Positive Free Cash Flow
  • Debt/EBITDA
  • ROE 42.9%
  • Analyst Consensus 76% Buy
  • PEG Ratio 0.47
  • Net Margin Trend 22.4% vs 10.1%

Reprovado (11)

  • Price CAGR -3.27%
  • P/FCF 1049.76
  • P/B Ratio 580.17
  • CapEx intensity
  • Current Ratio
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Revenue Growth 5Y 0.3%
  • Earnings Surprise avg 2.4%
  • Earnings Quality (OCF/NI) 0.66
  • Piotroski F-Score 1/9

Indisponível (6)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Share Dilution (missing shares data)

Piotroski F-Score

1/9

Preocupações financeiras graves

score
criteria

Qualidade dos Resultados

0.66

Moderada: alguma diferença entre lucros e caixa

Diluição de Ações

-

A recomprar ações. Favorável ao acionista

Governação

Equipa Executiva

NomeCargoIdade
Mr. Kristoffer Loe LichtCEO & Executive Director49
Ms. Shannon Sue EisenhardtCFO & Executive Director51
Mr. Nicholas James Ashworth C.F.A.Senior Vice President of Investor Relations-
Ms. Catheryn O'RourkeSenior VP, General Counsel & Company Secretary52
Ms. Sheila RedzepiChief Communications & Corporate Affairs Officer46
Mr. Ranjay RadhakrishnanChief Human Resources Officer54
Mr. Jerome LemairePresident North America51
Ms. Angela Naef Ph.D.Chief Research & Development Officer49
Ms. Susan SholtisPresident of Nutrition58
Dr. Alessio Fasano M.D.Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business-

Risco de Auditoria

4

Risco do Conselho

2

Risco de Remuneração

3

Risco dos Direitos dos Acionistas

1

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Latest News

Recent headlines for RBGPF, sourced from Markets Gazette.

No recent news for RBGPF.